Driving Cancer Discovery with Minimally Invasive, Treatment-Naive Samples

SAN DIEGO, Sept. 16, 2025 /PRNewswire/ — Sanguine Biosciences, a leading provider of healthy and disease-state human biospecimens and data for research, today announced the expansion of its oncology sample offerings through new partnerships with oncology clinics nationwide. These collaborations enable Sanguine to provide researchers with a broader range of high-quality, minimally invasive biospecimens, including treatment-naive samples critical for advancing cancer discovery and precision medicine.

Through these partnerships, Sanguine now offers researchers access to a growing inventory of oncology biospecimens, including blood, plasma, serum, and peripheral blood mononuclear cells (PBMCs), collected using minimally invasive methods to reduce donor burden and accelerate study timelines. Treatment-naive samples, in particular, provide researchers with rare and highly valuable insights into early disease biology, immune responses, biomarkers for diagnostic development, and potential therapeutic targets prior to intervention.

Sanguine leverages its integrated technology platform to streamline data and donor engagement. By securely importing electronic medical records (EMRs) directly from clinic systems, Sanguine harmonizes rich clinical data with each biospecimen, giving researchers a comprehensive, contextualized dataset. At the same time, individuals can be remotely consented into Sanguine’s donor community, allowing clinics and their patients to participate in research without additional infrastructure or operational burden. This seamless integration accelerates access to high-quality samples and data while preserving clinic workflows and patient experience.

“By leveraging our infrastructure, technology, and operations, Sanguine has partnered with over 20 oncology clinics across the United States to create a path for empowering researchers with timely access to a diverse group of highest-quality patient samples,” said Gerald Lee, co-founder and Chief Product Officer at Sanguine Biosciences. “Our expanded oncology offerings, especially treatment-naive biospecimens, will support breakthrough studies in biomarker discovery, drug development, and personalized cancer therapies.”

Sanguine’s expanded oncology capabilities complement its existing nationwide donor network, advanced logistics infrastructure, and robust data integration services, enabling researchers to obtain:

Treatment-naive oncology samples across multiple cancer types
Longitudinal and minimally invasive collections to track disease progression
Matched blood products, including plasma, serum, and PBMCs
Detailed electronic medical records, clinical, and demographic metadata to enhance translational insights

With cancer research evolving rapidly, access to high-quality, clinically annotated biospecimens remains a critical bottleneck. Sanguine’s latest initiative directly addresses this challenge, enabling academic institutions, biotech companies, and pharmaceutical researchers to accelerate discoveries and bring new diagnostics and therapies to patients faster.

For more information about Sanguine’s oncology biospecimen offerings or to request samples, visit www.sanguinebio.com .

Sanguine Biosciences is accelerating the adoption of personalized medicine by empowering patients with their healthcare data and facilitating participation in biomedical research. By merging annotated patient biospecimens with real-world and analytical data, Sanguine delivers actionable biomarker discovery and validation studies that bridge the gap between patients and scientists working on innovative therapies. In supporting translational and clinical research at 30 of the top 40 global pharmaceutical and biotechnology companies, Sanguine has accelerated R&D and increased confidence in drug development and manufacturing pipelines. For the past four years, Sanguine has received the prestigious designation as a “Great Places to Work” company.